Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;164(1):133-138.
doi: 10.1007/s10549-017-4220-x. Epub 2017 Apr 1.

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors

Wilfred Truin  1 , Rudi M H Roumen  1   2 , Sabine Siesling  3   4 , Koen K van de Vijver  5 , Vivianne C G Tjan-Heijnen  2 , Adri C Voogd  6   7   8
Affiliations

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors

Wilfred Truin et al. Breast Cancer Res Treat. 2017 Jul.

Abstract

Background: Differences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC.

Methods: We included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry. A semi-quantitative classification was used to analyze differences in ER/PR expression, which consisted of three ER expression classes: 10-69, 70-89, and ≥90%. Differences in ER and PR expression levels between IDC and ILC were analyzed according to age group, tumor size, axillary nodal status, grade, and HER2 status.

Results: In total, 26,339 ER and/or PR-positive breast cancers were included in the study, of which 17% were ILC and 83% IDC. In patients with IDC, 86% of the tumors showed an ER expression level of 90% or more, compared to 84% in those with ILC. In both IDC and ILC a PR expression level of 90% or more was observed in 54% of the tumors. In postmenopausal patients aged 50-69 years no significant differences could be observed in ER and PR expression levels between ILC and IDC.

Conclusion: Patients with ER and PR-positive ILC and IDC have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC.

Keywords: Estrogen receptor; Invasive ductal carcinoma; Invasive lobular carcinoma; Progesterone receptor.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Figures

Fig. 1
Fig. 1
Percentage of estrogen receptor (ER) expression in ER-positive invasive lobular (ILC) or invasive ductal (IDC) breast cancer
Fig. 2
Fig. 2
Percentage of progesterone receptor (PR) expression in PR-positive invasive lobular (ILC) or invasive ductal (IDC) breast cancer
See this image and copyright information in PMC

References

    1. Fortunato L, Mascaro A, Poccia I, et al. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? Analysis of an institutional database over a 10-year period. Ann Surg Oncol. 2012;19:1107–1114. doi: 10.1245/s10434-011-1907-9. - DOI - PubMed
    1. Guiu S, Wolfer A, Jacot W, et al. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? Crit Rev Oncol Hematol. 2014;92:235–257. doi: 10.1016/j.critrevonc.2014.07.003. - DOI - PubMed
    1. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533–1546. doi: 10.1093/annonc/mdv221. - DOI - PMC - PubMed
    1. Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010;17:2411–2418. doi: 10.1245/s10434-010-1008-1. - DOI - PMC - PubMed
    1. Petrelli F, Barni S. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1764 lobular breast cancer. Breast Cancer Res Treat. 2013;142:227–235. doi: 10.1007/s10549-013-2751-3. - DOI - PubMed

MeSH terms